Glenmark Pharmaceuticals announced that the United States Food & Drug Administration (USFDA) completed a Good Manufacturing Practice (GMP) inspection at the Company’s formulation manufacturing facility based out
of Chhatrapati Sambhaji Nagar (Aurangabad), India. The inspection was conducted from 9 September to 20 September, 2024. The inspection closed with no observation
of Chhatrapati Sambhaji Nagar (Aurangabad), India. The inspection was conducted from 9 September to 20 September, 2024. The inspection closed with no observation
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Sep 21 2024 | 12:53 PM IST
